Capital to outwit cancer

We are an oncology-focused investment fund established with The University of Texas MD Anderson Cancer Center to redefine funding and support for promising cancer therapies.

_________________________________________

Precision investing

New cancer treatments—immunotherapies, CAR-T and other cell therapy treatments, precision medicine and radiotherapeutics—are turning a cancer diagnosis into manageable diseases. However, these innovations are in need of capital, and, more important, clinical expertise.

Cancer Focus Fund was made for this moment.

Our rigorous methodology and unique relationship with MD Anderson Cancer Center set us apart.

We source the most intriguing oncology assets from around the world, and our Scientific Advisory Committee – featuring leading experts from MD Anderson – identify those ready for human clinical trials. With a keen eye on risks and rewards, our leadership narrows the list of candidates to only a few drugs worthy of investment.

Cancer Focus Fund combines decades of venture capital experience with the research and clinical trials expertise of MD Anderson. That’s how we deliver profits to investors and breakthroughs to patients facing cancer.

CFF Investments

Nectin Therapeutics develops a series of novel immunotherapeutic biological drugs, targeting receptors from the nectin protein family across various solid and hematological cancers. [More]
Eisbach Bio is focused on precision oncology. Based in Germany, the firm develops drugs that aim to disrupt tumor growth, going after genetic vulnerabilities within cancer cells. Eisbach pioneers first-in-class therapies with fewer side effects. [More]
Based in the Netherlands, ISA is developing fully synthetic immune therapies against cancer and persistent virus infections. The company has built a proprietary platform based on its synthetic long peptide technology. [More]
KAHR is leveraging proprietary technology to unmask cancer and simultaneously recruiting a targeted immune response. [More]

Mereo BioPharma develops innovative therapeutics for rare diseases. The firm trades on NASDAQ under the stock symbol MREO. [More]
Based in Houston, Texas, March Biosciences is a clinical-stage company in the cell therapy field focused on developing CAR-T cell strategies to address the most challenging hematological cancers. [More]
ImmunoGenesis is a clinical-stage biopharmaceutical company re-envisioning the treatment of cold tumors, which account for more than half of all cancers. [More]
Starget Pharma is an early-stage clinical company developing a new class of Smart Targeted Radioligands for precision oncology of hard-to-heal cancers. [More]